cologuard®

Backed by strong science and robust clinical research in collaboration with Mayo Clinic, Cologuard® is a stool DNA-based colorectal cancer screening test for average-risk individuals who are 45 or older. Cologuard uses a biomarker panel which analyzes a person's stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences' scientific platform.

Cologuard finds colon cancer even in early stages when it is more treatable.[1,2,3]

Cologuard is convenient. It's a noninvasive screening option that can be used at home that requires no special prep, no need for time off, no changes to your diet or medication. People can collect their Cologuard sample in the privacy of their own home. Cologuard includes a built-in patient navigation program with 24/7 patient support for questions and reminder texts and calls to support completion of the test.

VISIT COLOGUARD.COM

INNOVATION SUPPORTS THE COLOGUARD SCIENTIFIC PLATFORM

STOOL DNA ISOLATION | DNA STABILITY TECHNOLOGY | DNA BIOMARKER DETECTION | HEMOGLOBIN BIOMARKER DETECTION AND STABILITY TECHNOLOGY | POWERFUL MATHEMATICAL ALGORITHM

STOOL DNA ISOLATION

This proprietary technology proved to be a breakthrough in the development of the multitarget stool DNA test. Our scientists needed to first solve the essential problem of effectively isolating DNA from stool before achieving the goal of developing a noninvasive colon cancer screening test.

cologuard®

Backed by strong science and robust clinical research in collaboration with Mayo Clinic, Cologuard® is a stool DNA-based colorectal cancer screening test for average-risk individuals who are 45 or older. Cologuard uses a biomarker panel which analyzes a person's stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences' scientific platform.

Cologuard finds colon cancer even in early stages when it is more treatable.[1,2,3*]

Cologuard is convenient. It's a noninvasive screening option that can be used at home that requires no special prep, no need for time off, no changes to your diet or medication. People can collect their Cologuard sample in the privacy of their own home. Cologuard includes a built-in patient navigation program with 24/7 patient support for questions and reminder texts and calls to support completion of the test.

→ VISIT COLOGUARD.COM

INNOVATION SUPPORTS THE COLOGUARD

INNOVATION SUPPORTS THE COLOGUARD SCIENTIFIC PLATFORM

STOOL DNA ISOLATION | DNA STABILITY TECHNOLOGY | DNA BIOMARKER DETECTION | HEMOGLOBIN BIOMARKER DETECTION AND STABILITY TECHNOLOGY | POWERFUL MATHEMATICAL ALGORITHM

STOOL DNA ISOLATION

This proprietary technology proved to be a breakthrough in the development of the multitarget stool DNA test. Our scientists needed to first solve the essential problem of effectively isolating DNA from stool before achieving the goal of developing a noninvasive colon cancer screening test.

*Based on 5-year relative survival

INNOVATION SUPPORTS THE COLOGUARD SCIENTIFIC PLATFORM

STOOL DNA ISOLATION | DNA STABILITY TECHNOLOGY | DNA BIOMARKER DETECTION | HEMOGLOBIN BIOMARKER DETECTION AND STABILITY TECHNOLOGY | POWERFUL MATHEMATICAL ALGORITHM

DNA STABILITY TECHNOLOGY

The development of an enhanced DNA stabilizing buffer was a critical step in the process of creating a reliable at-home screening kit. With this advance, the DNA in stool samples is protected through the transport process and remains amenable to analysis once it arrives at our processing center.

INNOVATION SUPPORTS THE COLOGUARD SCIENTIFIC PLATFORM

STOOL DNA ISOLATION | DNA STABILITY TECHNOLOGY | DNA BIOMARKER DETECTION | HEMOGLOBIN BIOMARKER DETECTION AND STABILITY TECHNOLOGY | POWERFUL MATHEMATICAL ALGORITHM

DNA BIOMARKER DETECTION

We developed our proprietary QuARTS technology (Quantitative Allele-specific Real-time Target and Signal Amplification) which efficiently amplifies and quantifies two separate methylated DNA markers (NDRG4 and BMP3) along with seven distinct KRAS gene point mutations. The beta actin (ACTB) gene serves as a reference marker for quantitation of the total amount of human DNA in each sample.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.